Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Ventyx Biosciences Inc. shares valued at $127,182 were sold by Sandborn William J. on May 15. At $36.47 per share, Sandborn William J. sold 3,487 shares. The insider’s holdings dropped to 34,662 shares worth approximately $1.16 million following the completion of this transaction.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
Sponsored
Also, Mohan Raju sold 30,000 shares, netting a total of over 1,178,502 in proceeds. Following the sale of shares at $39.28 each, the insider now holds 1,543,126 shares.
Before that, Krueger Christopher W had sold 15,000 shares from its account. In a trade valued at $579,699, the Chief Business Officer traded Ventyx Biosciences Inc. shares for $38.65 each. Upon closing the transaction, the insider’s holdings decreased to 15,000 shares, worth approximately $9.24 million.
Analyzing VTYX Stock Performance
On Thursday, Ventyx Biosciences Inc. [NASDAQ: VTYX] plunged -6.88% to $33.45. The stock’s lowest price that day was $33.39, but it reached a high of $35.87 in the same session. During the last five days, there has been a drop of approximately -0.33%. Over the course of the year, Ventyx Biosciences Inc. shares have jumped approximately 2.01%. Shares of the company reached a 52-week high of $47.25 on 03/03/23 and a 52-week low of $27.75 on 04/10/23. A 50-day SMA is recorded $35.31, while a 200-day SMA reached $33.13. Nevertheless, trading volume fell to 0.58 million shares from 0.3 million shares the previous day.
Support And Resistance Levels for Ventyx Biosciences Inc. (VTYX)
According to the 24-hour chart, there is a support level at 32.60, which, if violated, would cause prices to drop to 31.76. In the upper region, resistance lies at 35.08. The next price resistance is at 36.72. RSI (Relative Strength Index) is 41.50 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.78, which suggests the price will decrease in the coming days. Percent R is at 94.64%, indicating bearish price movement. Stochastics %K at holding indicates that the stock is to be held.
Is Ventyx Biosciences Inc. subject to short interest?
Stocks of Ventyx Biosciences Inc. saw a sharp steep in short interest on Apr 27, 2023 dropping by -0.7 million shares to 7.29 million. Data from Yahoo Finance shows that the short interest on Mar 30, 2023 was 7.99 million shares. A decline of -9.6% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 8.08 of the overall float, the days-to-cover ratio (short ratio) decline to 8.08.
Which companies own the most shares of Ventyx Biosciences Inc. (VTYX)?
According to Fidelity Management & Research Co filings, the company currently owns 6,697,737 shares, which is about 11.51% of the total VTYX shares outstanding. The investor’s shares have appreciated by 5,176,390 from its previous 13-F filing of 1521347.0 shares. With the completion of the sale transaction, Citadel Advisors LLC’s stake is now worth $113,282,521. T. Rowe Price Associates, Inc. acquire a 48.74% interest valued at $100.98 million while Capital Research & Management Co purchased a 263,040 stake. A total of 632,800 shares of Ventyx Biosciences Inc. were bought by Avidity Partners Management LP during the quarter, and 15,983 were bought by BlackRock Fund Advisors. In its current portfolio, The Vanguard Group, Inc. holds 1,745,283 shares valued at $65.62 million.
In terms of Ventyx Biosciences Inc. share price expectations, FactSet research, analysts set an average price target of $57.58 in the next 12 months, up nearly 54.51% from the previous closing price of $35.92. Analysts anticipate Ventyx Biosciences Inc. stock to reach $77.00 by 2023, with the lowest price target being $45.00. In spite of this, 12 analysts ranked Ventyx Biosciences Inc. stock as a Buy at the end of 2023.